Kal Sundaram, Chief Executive Officer at Taro Pharmaceutical Industries Ltd, the Israeli subsidiary of Sun Pharmaceutical Industries Ltd, will step down by the end of this calendar year. Sundaram will return to India to take up an executive position at Sun Pharma after the completion of his assignment at Taro at the end of 2016.

Kalyanasundaram Subramanian, known as Kal Sundaram, became CEO of Taro in April 2012. He had been Sun Pharma’s CEO since April 2010 and played a role in accelerating the company’s growth in India and other emerging markets.

• Taro Pharmaceutical is the US arm of Sun Pharma. Sun Pharma acquired a controlling stake in Taro in 2010.
• Sundaram has 3 decades of experience, much of which has been in the pharmaceutical industry, largely with GlaxoSmithKline Plc. (GSK), where he has held country, regional and global responsibilities. Sundaram left GSK India as its managing director.
• Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai,
• Founder: Dilip Shanghvi